Fig. 2
From: GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
In vivo anti-tumor activity of ex vivo GD2-BsAb or HER2- BsAb-armed T cells (EATs). a Anti-tumor activities of GD2-EATs and HER2-EATs were tested over a range of BsAb arming concentrations in vivo. b GD2-EATs (10 μg of GD2-BsAb/2 × 107 cells) and HER2-EATs (10 μg of HER2-BsAb/2 × 107 cells) exerted a potent anti-tumor effect against a variety of osteosarcoma PDXs without significant toxicity, improving survival